Siemens, BIR partner on research award
October 2, 2018 -- Siemens Healthineers is partnering with the British Institute of Radiology (BIR) on the BIR/Siemens Research Award to provide support to researchers in the fields of radiology, radiotherapy, oncology, radiography, or medical physics.
Hologic points to results of breast density survey
October 2, 2018 -- Women's imaging firm Hologic is highlighting survey results that suggest more than 60% of women are unaware of how breast density affects their risk of developing cancer.
Phillips-Hughes inaugurated as new BIR president
September 28, 2018 -- Dr. Jane Phillips-Hughes has been inaugurated president of the British Institute of Radiology (BIR). She takes over the position from Dr. Andy Rogers and will serve through 2020.
Sonoscanner develops new catheter placement device
September 28, 2018 -- French portable ultrasound developer Sonoscanner has partnered with single-use medical device manufacturer Vygon to develop an ultrasound scanner for catheter placement guidance.
Siemens Healthineers partners with Storz Medical
September 26, 2018 -- Siemens Healthineers and Storz Medical plan to sign a sales partnership agreement to market each other's products for diagnostic imaging in urology and noninvasive and minimally invasive therapy.
Brainlab teams up with Magic Leap
September 26, 2018 -- Image-guided therapy firm Brainlab has formed a partnership with spatial computing technology developer Magic Leap.
Elekta brings Unity to London
September 26, 2018 -- Radiation oncology vendor Elekta has installed its Unity MR/radiation therapy system at the Royal Marsden and the Institute of Cancer Research in London.
Esaote partners with BioRobotics Institute
September 25, 2018 -- Italian ultrasound vendor Esaote has collaborated with the BioRobotics Institute in Italy to develop an automated system for testing the reliability of manufactured ultrasound probes.
Accuray highlights CyberKnife prostate studies
September 25, 2018 -- Radiation oncology firm Accuray is directing attention to two large multicenter studies that evaluated the use of its CyberKnife system for treating low- and intermediate-risk prostate cancer.